The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer.

@article{Baumann1990TheDV,
  title={The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer.},
  author={Michael Baumann and A Kappl and Thomas Lang and Karl Brand and Wolfgang Siegfried and E. M. Paterok},
  journal={Cancer investigation},
  year={1990},
  volume={8 3-4},
  pages={351-6}
}
The diagnostic validity of the glycolytic enzyme phosphohexose isomerase (PHI) as a serum tumor marker was evaluated. For this purpose the sensitivity of PHI was determined in 435 patients with histopathologically defined, malignant gastrointestinal, kidney, and mammary tumors prior to primary treatment. To assess the specificity, PHI serum activities were… CONTINUE READING